Delonix Bioworks Partners with A*STAR Labs to Innovate OMV Vaccines Against Klebsiella pneumoniae
Collaboration Between Delonix Bioworks and ASTAR Infectious Diseases Labs
In a groundbreaking move towards combating antimicrobial resistance, Delonix Bioworks—a clinical-stage biotechnology firm focusing on next-generation outer membrane vesicle (OMV) vaccines—has announced a research collaboration with the ASTAR Infectious Diseases Labs (ASTAR IDL) based in Singapore. This partnership is officially documented in a Research Collaboration Agreement aiming to discover and develop novel OMV vaccine candidates targeting the dangerous pathogen Klebsiella pneumoniae.
The Urgent Need for Vaccines
Klebsiella pneumoniae is notorious for causing severe health issues, including life-threatening pneumonia, bloodstream infections, and sepsis, especially among vulnerable populations. The World Health Organization (WHO) has marked carbapenem-resistant Enterobacterales, which includes K. pneumoniae, as critical-priority pathogens due to their high level of multi-drug resistance against conventional therapies. Currently, no licensed vaccines exist for K. pneumoniae, which is alarming given its public health implications.
Traditional vaccine methods have struggled due to the organism’s genetic diversity, an extraordinarily thick capsular structure that masks vital surface antigens, and notable antigen variation across its hypervirulent and multidrug-resistant strains. Delonix’s innovative OMV methodology seeks to tackle these hurdles effectively.
Innovative Approach
Delonix Bioworks employs engineered OMVs as a promising solution. By utilizing advanced genomic editing techniques, the company can adapt the bacterial genome to minimize capsular interference, detoxify harmful endotoxins, and assemble conserved native antigens onto non-replicating vesicles. This capability aims to foster robust innate and adaptive immune responses, offering enhanced cross-strain protection against K. pneumoniae.
Delonix's approach is not just a technical achievement but a potential game-changer in the fight against antimicrobial resistance. The collaboration with ASTAR IDL, which excels in translational infectious disease research and immunological evaluation, further solidifies Singapore's position in turning research findings into actionable medical interventions. Together, they will evaluate vaccine candidates for critical metrics such as safety and immunogenicity.
Progress Towards a Better Future
This collaboration is particularly important given the escalating threat of antimicrobial resistance (AMR). Delonix Bioworks aims to leverage its comprehensive OMV Plus™ platform, combined with ASTAR IDL’s expertise, to produce vaccines that are not only effective but also feasible in terms of rapid deployment in clinical settings.
Delonix already has a robust pipeline of innovative bacterial vaccine candidates that address various unmet medical needs, including vaccines for infections caused by meningococcal group B, pertussis, gonorrhea, and now K. pneumoniae. Their lead candidate, DX-104, is currently undergoing Phase I clinical trials in both Australia and China and reflects Delonix’s commitment to pioneering infectious disease solutions.
In summary, the collaboration between Delonix Bioworks and ASTAR IDL marks a pivotal advance towards developing preventive measures against drug-resistant Klebsiella pneumoniae, a pathogen of urgent public health concern. With continued dedication and innovative research endeavors, this partnership aims not only to innovate in vaccine technology but also to offer hope for global health advances against AMR—an increasing threat in today’s healthcare landscape.